-
Effect of Novel Neuronal Nicotinic Receptor Compounds on Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
… nervous system for their ability to reduce L-dopa-induced dyskinesias (LIDs). Using a well-validated model of …
-
Evaluation of the striatum-enriched genes, CalDAG-GEF1 and CalDAG-GEF2, as targets for the treatment and prevention of L-DOPA induced dyskinesias
… to L-DOPA, including abnormal involuntary movements termed dyskinesias. We seek to understand the basis of these …
-
The Parkinson's Minute: A Promising Target to Treat Dyskinesia
June 13, 2012
… person with Parkinson’s disease (PD) who is struggling with dyskinesia, the often uncontrollable movements that are a … side effect of PD drugs. “I just can’t wait for a cure for dyskinesia, if not Parkinson’s,” she says. Dyskinesia is a …
-
The role of striatal serotonergic terminals in L-dopa induced-dyskinesia in PD patients: An in vivo PET study
… disease (PD), L-dopa induced-involuntary movements or dyskinesias. They believe that when many of the dopamine …
-
First Drug Approved for Dyskinesia in Parkinson's Disease
August 24, 2017
… (amantadine extended release capsules) for the treatment of dyskinesia in people with Parkinson's who are taking … formulation of amantadine (GOCOVRI) to treat dyskinesia in Parkinson's disease (PD). This is the first …
-
Podcast: Measuring Feeling and Functional Impact of Dyskinesia
September 20, 2017
… MD, of Rush University in Chicago discusses the Unified Dyskinesia Rating Scale. He led the development of the scale … Michael J. Fox Foundation -- which measures the impact of dyskinesia including patient perceptions. Dyskinesia is …